Novo Nordisk (Ozempic)

3666.343 - 3691.699 David Rosenthal

And, you know, that's all well and good to be a diversified, you know, industrial conglomerate, except the enzyme business is both capital intensive and not that profitable. Those don't mix well. Yeah, those don't tend to mix well. Now, it's still a viable business. It actually stays part of Novo and then Novo Nordisk all the way until the year 2000 when it gets spun out. Oh, is this Novozymes?